A comparison of neurocognitive profiles of patients with confirmed Niemann-Pick disease type C (NP-C) and early Alzheimer disease found that general dementia screening assessments should not be used alone to evaluate cognitive performance in patients with suspected NP-C since these patients may demonstrate milder cognitive deficits than patients with early Alzheimer disease.
The rare disease, Niemann-Pick disease type C (NP-C), is a progressive neurodegenerative disease caused by mutations in the NPC1 or the NPC2 gene. Although a disease-specific therapy is available, a recent study in Orphanet Journal of Rare Diseases aimed to distinguish clinically between the cognitive profiles in NP-C and primary dementia.
The study compared neurocognitive profiles of patients with confirmed NP-C and early Alzheimer disease (eAD). All patients in the study underwent neurocognitive assessment using dementia screening tests and other extensive tests that aimed to assess verbal memory, visuoconstructive abilities, visual memory, executive functions, and verbal fluency. According to the authors, cognitive impairment before the age of 65 is a characterization of early-onset cognitive decline, which is being increasingly reported. Most of those cases are related to eAD.
“However, compared to dementia in patients aged > 65 years, there is a much wider range of differential diagnoses, including underlying inherited neurodegenerative aetiologies such as NP-C,” explained the authors.
All of the study participants underwent follow-up visits for at least 12 months and their functional disability was evaluated in patients with NP-C using a disease-specific scale which assessed 6 key domains—ambulation, manipulation, language, swallowing, ocular movements, and epilepsy—on a scale of 0 (best) to 24.
The results showed that overall cognitive impairment was significantly higher in eAD versus NP-C. Also, the frequency of patients who were classified as cognitively impaired was greater in eAD versus NP-C.
Those with NP-C demonstrated relatively preserved verbal memory, but frequent impairment in visual memory, visuoconstruction, executive functions and specifically in verbal fluency. The eAD group demonstrated a wider profile of more frequent and more severe neurocognitive deficits, specifically featuring severe verbal and visual memory deficits with major executive impairment.
“Overall, taking patient age, gender, and education into account, eAD patients showed wider, more generalised impairments in affected cognitive domains compared with the profile seen in NP-C patients in the current study,” concluded the researchers. “Deficits were also more frequent and greater in magnitude in eAD on most of the neurocognitive tests that we employed.”
Based on the results, the researchers recommended that general dementia screening assessments should not be used alone to evaluate cognitive performance in patients with suspected NP-C since these patients may demonstrate milder cognitive deficits than eAD patients.
The researchers call for future studies with larger numbers of patients in order to gain further insight into the assessment of NP-C and other diseases.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
Data Show Undocumented Latinx People Face Disproportionate Burden of Long COVID
October 17th 2024New findings show that undocumented Latinx immigrants, who make up 7% of the US population, face significant challenges in accessing health care due to uninsurance, limited access to care, language barriers, and fears surrounding their immigration status.
Read More